The purpose of this
retrospective study was to provide additional data on the use of toceranib in a wide variety of
tumor types in small breed
dogs, especially < 8 kg (except 5
dogs). This was a
retrospective study of 31
dogs with malignant
tumors treated with a 2.5 mg/kg median
dose of toceranib (Palladia; Zoetis, Florham Park, NJ, USA) on a Monday–Wednesday–Friday
schedule. Clinical benefit was observed in 13 of 15
dogs (86.7%, 3 with complete response, 4 with partial response, 6 with stable
disease) with gross
disease. Distant
metastasis, response to
treatment, and
treatment setting were significantly associated with
survival time. Negative
prognostic factors were multiple
chemotherapy and distant
metastasis (affecting
progression-free survival [PFS]),
surgery, regional enlarged
lymph nodes, underlying
disease, and
toxicity (affecting median
survival time [MST]). Positive
prognostic factors were epithelial and round
cell tumor (affecting PFS), epithelial
tumor, microscopic
disease, no evidence of
disease response, and stable
disease (MST). In conclusion, a clinical benefit from toceranib
treatment was noted in most of the
dogs with gross
disease in our study. This study suggested that the toceranib is probably selective
treatment to various
tumor types in small breed
dogs.